TVARDI THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- TVARDI THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $107.00K.
- TVARDI THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $421.00K.
- TVARDI THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $3.00K, a 40.00% decline year-over-year.
- TVARDI THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $5.00K, a 99.11% decline year-over-year.
- TVARDI THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $532.00K, a 10540.00% increase from fiscal 2024.
- TVARDI THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $5.00K, a 99.11% decline from fiscal 2023.
- TVARDI THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $560.00K, a 80.06% increase from fiscal 2022.
- TVARDI THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $311.00K, a 81.03% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-12-31 | $532.00K 10-K · filed 2026-03-31 | |
| 2025-09-30 | $107.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $421.00K 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $3.00K 10-Q · filed 2026-08-14 | |
| 2024-12-31 | $5.00K 10-K · filed 2026-03-31 | |
| 2024-03-31 | $5.00K 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $560.00K 10-K · filed 2025-03-11 | |
| 2023-03-31 | $560.00K 10-Q · filed 2024-11-14 | |
| 2022-12-31 | $311.00K 10-K · filed 2025-03-11 | |
| 2022-09-30 | $104.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $182.00K 10-Q · filed 2023-11-13 | |
| 2022-03-31 | $3.00K 10-Q · filed 2023-11-13 | |
| 2021-12-31 | $1.64M 10-K · filed 2024-03-06 | |
| 2021-09-30 | $339.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $293.00K 10-Q · filed 2022-11-07 | |
| 2021-03-31 | $688.00K 10-Q · filed 2022-11-07 | |
| 2020-12-31 | $691.00K 10-K · filed 2023-03-06 | |
| 2020-09-30 | $395.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $201.00K 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $75.00K 10-Q · filed 2021-11-08 | |
| 2019-12-31 | $6.11M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $1.84M 10-Q · filed 2020-11-09 | $6.61M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $3.98M 10-Q · filed 2020-11-09 | $6.66M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $234.00K 10-Q · filed 2020-11-09 | $4.17M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $558.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $4.19M 10-K · filed 2021-02-25 |
| 2018-09-30 | $1.89M 10-Q · filed 2019-11-05 | $3.82M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $1.49M 10-Q · filed 2019-11-05 | $2.08M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $263.00K 10-Q · filed 2019-11-05 | $1.81M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $183.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $1.70M 10-K · filed 2020-02-27 |
| 2017-09-30 | $151.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $1.60M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $1.45M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | $149.00K 10-Q · filed 2018-05-09 | $232.00K derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | $83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $123.00K 10-K · filed 2019-03-12 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $79.00K derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $367.00K derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-03-31 | $40.00K 10-Q · filed 2017-05-04 | $396.00K derived: sum of 4 quarters · filed 2018-03-15 |
| 2015-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $362.00K 10-K · filed 2018-03-15 |
| 2015-09-30 | $288.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $332.00K derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | $29.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $134.00K derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | $6.00K 10-Q · filed 2016-05-05 | |
| 2014-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $128.00K 10-K · filed 2017-03-10 |
| 2014-09-30 | $90.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | |
| 2012-12-31 | $55.00K 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |